Haploidentical transplantation with post-transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F20%3A00012991" target="_blank" >RIV/00023736:_____/20:00012991 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1016/j.bbmt.2020.01.003" target="_blank" >https://doi.org/10.1016/j.bbmt.2020.01.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.bbmt.2020.01.003" target="_blank" >10.1016/j.bbmt.2020.01.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Haploidentical transplantation with post-transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Popis výsledku v původním jazyce

Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting.

Název v anglickém jazyce

Haploidentical transplantation with post-transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Popis výsledku anglicky

Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biology of blood and marrow transplantation

ISSN

1083-8791

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

936-942

Kód UT WoS článku

000531098000020

EID výsledku v databázi Scopus

2-s2.0-85080084689